The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The primary objectives of the ORIGIN study were:
- To determine whether insulin glargine-mediated normoglycemia can reduce cardiovascular
morbidity and/or mortality in people at high risk for vascular disease with either
Impaired Fasting Glucose (IFG), Impaired Glucose Tolerance (IGT) or early type 2
diabetes;
- To determine whether omega-3 fatty acids can reduce cardiovascular mortality in people
with IFG, IGT or early type 2 diabetes.
The secondary objectives of the insulin glargine study were to determine if insulin
glargine-mediated normoglycemia can reduce:
- total mortality (all causes);
- the risk of diabetic microvascular outcomes;
- the rate of progression of IGT or IFG to type 2 diabetes.